Cambridge-based Infinity Pharmaceuticals Inc. said that its 5.7 million-share offering priced flat with Wednesday’s close of $26.33, as it seeks to raise funds for research and development costs, potential acquisitions and other purposes, Dow Jones reported. Infinity’s shares had climbed to their highest level in a decade on Tuesday after the company reported positive results from an early clinical trial of its drug IPI-145 as a treatment for blood cancers.
Infinity completes 5.7m share offering
December 14, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢